Embla Medical Recognized for Leadership in Accessibility and International Reach
Company honored by Forbes Magazine for Championing Accessibility and by Iceland's President for Excellence in Global Exports REYKJAVÍK, Iceland, June 18, 2025 /PRNewswire/ -- Embla Medical (NASDAQ Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, is being internationally recognized for its pioneering role in enhancing peoples' mobility and its business leadership, the company...
Largest Australian Health Insurer to Fund Innovative PTSD Treatment Program
PERTH, Australia, June 18, 2025 /PRNewswire/ -- Emyria Limited (ASX: EMD) ("Emyria", or the "Company") a leader in developing and delivering innovative mental health treatments, today announced a landmark partnership with Medibank, Australia's largest private health insurer. Under the multi-year agreement, eligible Medibank members can now access Emyria's Empax PTSD care program with...
Novo Holdings Reports Strong Momentum in Asia Across Healthcare and Planetary Health in 2024
Landmark investments, portfolio progress, and expanded presence position Novo Holdings for long-term growth and impact in Asia SINGAPORE, June 18, 2025 /PRNewswire/ -- Novo Holdings today released its Asia Investments Year in Review 2024, highlighting a year of strategic growth and purpose-driven investing across healthcare, life sciences, and planetary health in key Asian markets. The report underscores...
LA ROCHE-POSAY RAISES RM 100,000 TO NARROW MALAYSIA’S DERMATOLOGY CARE GAP
KUALA LUMPUR, Malaysia, June 18, 2025 /PRNewswire/ -- With fewer than 200 trained dermatologists serving Malaysia's 33 million people—just one specialist for every 165,000 residents—qualified skin care is out of reach for many. This acute shortage fuels La Roche-Posay's mission to bring dermatologist-approved skincare closer to those who need it. The Malaysian Skin...
Angel Yeast Marks Sustainable Gastronomy Day with Outstanding Results in Weight Management Year
YICHANG, China, June 18, 2025 /PRNewswire/ -- Angel Yeast (SH:600298), a global leader in yeast manufacturing, is celebrating Sustainable Gastronomy Day (June 18) by promoting low-carbon healthy diet solutions as part of its ongoing mission to reshape the nutritional health landscape. This initiative expands on the company's "Weight Management Year" program...
WuXi AppTec Earns SBTi Validation for Near-Term Emissions Reduction Targets
SHANGHAI, June 18, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that the Science Based Targets initiative (SBTi) has approved WuXi AppTec's near-term science-based emissions reduction targets. The validation of these targets affirms that the Company's planned reduction...
Peer-Reviewed Study in Nature Scientific Reports Demonstrates Non-Invasive Fat Reduction Using Alma’s Energy-Based Technology
CAESAREA, Israel, June 18, 2025 /PRNewswire/ -- A newly published, peer-reviewed study in Nature Scientific Reports, part of the prestigious Nature Portfolio, presents compelling clinical evidence on the effectiveness of non-invasive energy-based technology for abdominal fat reduction. The study demonstrated statistically significant decreases in abdominal fat layer thickness in Korean women with...
AI-Powered CDSS Enhances Patient Safety with Real-World Data
SAN FRANCISCO, June 18, 2025 /PRNewswire/ -- The growing demand for personalized medicine has accelerated the adoption of Real-World Data (RWD) in healthcare. The Tungs' Taichung MetroHarbor Hospital in Taiwan, in collaboration with AESOP Technology, conducted research on an AI-driven Clinical Decision Support System (CDSS) that leverages RWD to enable safer and more effective clinical decision-making, significantly reducing the...
RemeGen’s Telitacicept (RC18) Received Orphan Drug Designation from EMA for Myasthenia Gravis
YANTAI, China, June 17, 2025 /PRNewswire/ -- On June 16, 2025, RemeGen Co., Ltd. ("RemeGen", stock symbols: 688331.SH/09995.HK) announced that telitacicept (RC18; brand name: 泰爱®) has received Orphan Drug Designation (ODD) from European Medicines Agency (EMA) for the treatment of Myasthenia Gravis (MG), marking a key milestone achieved in its global development....
Skyhawk Therapeutics Announces First Patient Dosed in Phase 2/3 FALCON-HD Trial of SKY-0515 for Huntington’s Disease
SKY-0515 is an oral small molecule designed to reduce the production of both huntingtin (HTT) and PMS1 proteins—two key drivers of HD pathology Initiation of the FALCON-HD trial follows promising Phase 1 results demonstrating up to 72% reduction in HTT mRNA in healthy volunteers The SKY-0515 Phase...
